Q-omics provides the consensus-scored TCEAL3 profile across patient tissues and cancer cell-line models. TCEAL3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCEAL3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TCEAL3 protein abundance shows 27,706 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KIRC, and BRCA as cancer lineages where TCEAL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEAL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEAL3 survival associations across molecular data types. TCEAL3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEAL3 RNA expression–survival associations across cancer types. High TCEAL3 expression shows unfavorable associations in UVM and KIRP, but favorable associations in THCA, PAAD, LGG and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TCEAL3 RNA expression.
This table summarizes TCEAL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCEAL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEAL3 shows lower tumor expression in KIRC, KICH, THCA, BLCA and KIRP and higher tumor expression in HNSC. The KIRC box plot shows higher TCEAL3 RNA expression in normal versus tumor tissue (log2 FC = −1.109, t-test p < 0.001).
This table shows molecular features associated with TCEAL3 in patient tissues and cancer cell lines. In patient samples, TCEAL3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEAL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
